Fed Clinical Trial
Official title:
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories, Ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr Tablets in Healthy Adult Male Volunteers Under Fed Conditions
Galantamine Hydrobromide Tablets, Bioequivalence study of Dr. Reddy's under Fed condition.
Status | Completed |
Enrollment | 24 |
Est. completion date | November 2004 |
Est. primary completion date | November 2004 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: Subject candidates must fulfill all of the following inclusion criteria to be eligible for participation in the studyI unless otherwise specified: - Healthy adult male volunteers, 18-55 years of age; - Weighing at least 60 kg and within 15% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Ufe Insurance Company, 1983); - Medically healthy subjects with clinically normal laboratory profiles, vital signs and ECGs; - Give voluntary written informed consent to participate in the study. Exclusion Criteria: Subject candidates must not be enrolled in the stUdy if they meet any of the following criteria: - History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease. - In addition, history or presence of: - alcoholism or drug abuse within the past year; - hypersensitivity or idiosyncratic reaction to galantamine or other anticholinesterase inhibitors; - asthma and seizures. - Subjects who tested positive at screening for HIV, HbsAg or HCV. - Subjects whose PR interval is >200 msec at screening and prior to dosing. - Subjects whose QTc interval is >450 msec at screening and prior to dosing. - Subjects who have used any drugs or substances known to be strong inhibitors of CYP enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first dose. - Subjects who have used any drugs or substances known to be strong inducers of CYP enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first dose. - Subjects who have been on a special diet (for whatever reason) during the 28 days prior to the first dose and throughout the study. - Subjects who, through completion of the stUdy, would have donated in excess of: 500 mL of blood in 14 days; 1500 mL of blood in 180 days; 2500 mL of blood in 1 year. - Subjects who have participated in another clinical trial within 28 days prior to the first dose. |
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Dr. Reddy's Laboratories Limited |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bioequivalence on Cmax and AUC parameters | 2 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01721187 -
Satiety Effects on the Neural Valuation of Food
|
N/A | |
Completed |
NCT01827878 -
Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed Conditions
|
Phase 1 | |
Completed |
NCT01283932 -
Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fed Condition
|
Phase 1 | |
Completed |
NCT03390881 -
Use of Breath Acetone aa a Marker of Energy Balance
|
N/A | |
Completed |
NCT01283867 -
Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Non-Fasting Conditions
|
Phase 1 | |
Completed |
NCT01503450 -
Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition
|
Phase 1 | |
Completed |
NCT01735383 -
Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fed Condition
|
Phase 1 | |
Completed |
NCT01618760 -
Bioequivalence Study of Risperidone Tablet 1 mg Under Fed Condition
|
Phase 1 | |
Completed |
NCT01578265 -
Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fed Condition
|
Phase 1 | |
Recruiting |
NCT05837572 -
Development of the Leeds Food Preference Questionnaire in Spanish
|
N/A | |
Completed |
NCT01618825 -
Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fed Condition
|
Phase 1 | |
Completed |
NCT01505998 -
Bioequivalence Study of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg Capsules of Dr. Reddy's Under Fed Conditions
|
Phase 1 | |
Completed |
NCT01735344 -
Bioequivalence Study of Lisinopril Tablets 40 mg Under Fed Condition
|
Phase 1 | |
Completed |
NCT01372358 -
Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions
|
Phase 1 | |
Completed |
NCT01567501 -
Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed Condition
|
Phase 1 | |
Completed |
NCT05995119 -
Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers
|
Early Phase 1 | |
Completed |
NCT01314352 -
Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions
|
Phase 1 | |
Completed |
NCT01744873 -
Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fed Condition
|
Phase 1 | |
Completed |
NCT01503424 -
Bioequivalence Study of Olanzapine Tablets, 5 mg Under Fed Study
|
Phase 1 | |
Completed |
NCT01884909 -
Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fed Conditions
|
Phase 1 |